The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

Pharmacogenetics and Genomics

Volumn 22, Issue 5, 2012, Pages 373-380

  Elens, Laure ^a,c   Bouamar, Rachida ^b   Hesselink, Dennis A ^a   Haufroid, Vincent ^c   Van Gelder, Teun ^a,b   Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Departments of Hospital Pharmacy   (Netherlands)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

cyclosporine; CYP3A4; cytochrome P450 3A4; kidney transplantation; pharmacogenetics; single nucleotide polymorphism; toxicity; z.ast; 22

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; CYTOCHROME P450 3A4; GENOMIC DNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DIABETIC NEPHROPATHY; DNA EXTRACTION; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GLOMERULONEPHRITIS; GRAFT REJECTION; HETEROZYGOSITY; HLA MATCHING; HUMAN; HYPERTENSIVE NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; INTRON; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY GRAFT; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PYELONEPHRITIS; REFLUX NEPHROPATHY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84859900517     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328351f3c1     Document Type: Article

References (50)

1. Hesselink DA, Smak Gregoor PJ,Weimar W. The use of cyclosporine in renal transplantation. Transplant Proc 2004; 36:99S-106S. (Pubitemid 38373840)
2. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004; 68:1889-1902. (Pubitemid 39278511)
3. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharmacol 2009; 6:1631-1643.
4. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002; 3:561-597. (Pubitemid 35331660)
5. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294. (Pubitemid 35284253)
6. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423. (Pubitemid 24229655)
7. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 50-upstream regulatory region. Biochem Biophys Res Commun 1999; 259:201-205. (Pubitemid 29264018)
8. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31:755-761. (Pubitemid 36617664)
9. Van Schaik RH. CYP3A4, CYP3A5 and MDR-1 variants alleles in the Dutch Caucasian population. Clin Pharmacol Ther 2003; 73:42.
10. Rebbeck TR, Jaffe JM,Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229. (Pubitemid 28407089)
11. Amirimani B, Ning B, Deitz AC,Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42:299-305. (Pubitemid 38054375)
12. Felix CA,Walker AH, Lange BJ,Williams TM, Winick NJ, Cheung NK, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95:13176-13181. (Pubitemid 28509544)
13. Lamba JK, Lin YS, Thummel K, Daly A,Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132. (Pubitemid 34298916)
14. Wang D, Guo Y,Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11:274-286.
15. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57:1574-1583.
16. Elens L, van Schaik RH, Panin N, de Meyer M,Wallemacq P, Lison D, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12:1383-1396.
17. Van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86:1043-1051.
18. Van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, et al. UGT1A9 - 275T> A/-2152C > T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009; 86:319-327.
19. Van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, et al. AcylMPAG plasma concentrations and mycophenolic acidrelated side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit 2008; 30:439-444.
20. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit 2011; 33:178-184.
21. Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18:339-348. (Pubitemid 351367527)
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
23. Gaut BS, Long AD. The lowdown on linkage disequilibrium. Plant Cell 2003; 15:1502-1506. (Pubitemid 36872592)
24. Lebranchu Y, Halimi JM, Bock A, Chapman J, Dussol B, Fritsche L, et al. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. Transplant Proc 2005; 37:345-347. (Pubitemid 40459780)
25. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
26. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22:2107-2118.
27. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333. (Pubitemid 37509740)
28. Larsen CP, Grinyo J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528-1535.
29. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFITstudy). Am J Transplant 2010; 10:535-546.
30. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76:545-556. (Pubitemid 39601545)
31. Wallemacq PE, Alexandre K. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays. Clin Chem 1999; 45:432-435. (Pubitemid 29114189)
32. Bowers LD. Studies of cyclosporine and metabolite toxicity in renal and hepatocyte culture systems. Transplant Proc 1990; 22:1135-1136. (Pubitemid 20205481)
33. Copeland KR, Thliveris JA, Yatscoff RW. Toxicity of cyclosporine metabolites. Ther Drug Monit 1990; 12:525-532.
34. Copeland KR, Yatscoff RW. Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation 1992; 53:640-645.
35. Lemoine A, Azoulay D, Gries JM, Dennison A, Castaing D, Fredj G, et al. Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation 1993; 56:1410-1414. (Pubitemid 24018796)
36. Schmidt LE, Rasmussen A, Kirkegaard P, Dalhoff K. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. Transplantation 2003; 76:358-363. (Pubitemid 36927999)
37. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50:52-59. (Pubitemid 26250074)
38. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30:1108-1114.
39. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, Melvin WT. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 1999; 79:1836-1842. (Pubitemid 29132313)
40. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478. (Pubitemid 30183327)
41. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A ''silent'' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528. (Pubitemid 46175758)
42. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33. (Pubitemid 38130115)
43. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C >T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704. (Pubitemid 41345321)
44. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-1511. (Pubitemid 41716536)
45. Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 2009; 20:1404-1415.
46. Ansermot N, Rebsamen M, Chabert J, Fathi M, Gex-Fabry M, Daali Y, et al. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab Lett 2008; 2:76-82. (Pubitemid 351983779)
47. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36. (Pubitemid 34119193)
48. Dominguez J, Lira F, Troncoso P, Aravena C, Ortiz M, Gonzalez R. Factors that predict duration of delayed graft function in cadaveric kidney transplantation. Transplant Proc 2009; 41:2668-2669.
49. Goh CC, Ladouceur M, Peters L, Desmond C, Tchervenkov J, Baran D. Lengthy cold ischemia time is a modifiable risk factor associated with low glomerular filtration rates in expanded criteria donor kidney transplant recipients. Transplant Proc 2009; 41:3290-3292.
50. Ohlman S, Lindholm A, Hagglund H, Sawe J, Kahan BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993; 44:265-269. (Pubitemid 23096155)